Analyze Diet
Equine veterinary journal2006; 38(4); 342-346; doi: 10.2746/042516406777749245

Pharmacokinetics of danofloxacin in horses after intravenous, intramuscular and intragastric administration.

Abstract: Danofloxacin is a fluoroquinolone developed for veterinary medicine showing an excellent activity. However, danofloxacin pharmacokinetics profile have not been studied in horses previously. Objective: To study the pharmacokinetics following i.v., i.m. and intragastric (i.g.) administration of 1.25 mg/kg bwt danofloxacin to 6 healthy horses. Methods: A cross-over design was used in 3 phases (2 x 2 x 2), with 2 washout periods of 15 days (n = 6). Danofloxacin (18%) was administered by i.v. and i.m. routes at single doses of 1.25 mg/kg bwt. For i.g. administration an oral solution was prepared and administered via nasogastric tube. Danofloxacin concentrations were determined by HPLC assay with fluorescence detection. Tolerability at the the site of i.m. injection was monitored by creatine kinase (CK) activity. Results: Danofloxacin plasma concentration vs. time data after i.v. and i.g. administration could best be described by a 2-compartment open model. The disposition of i.m. administered danofloxacin was best described by a one-compartment model. The terminal half-lives for i.v., i.m. and i.g. routes were 6.31, 5.36 and 4.74 h, respectively. Clearance value after i.v. dosing was 0.34 l/kg bwt/h. After i.m. administration, absolute bioavailability was mean +/- s.d. 88.48 +/- 11.10% and Cmax was 0.35 +/- 0.05 mg/l. After i.g. administration, absolute bioavailability was 22.36 +/- 6.84% and Cmax 0.21 +/- 0.07 mg/l. CK activity following i.m. dosing increased 3-fold over pre-injection levels 12 h after dosing and subsequently approached (but did not reach) normal values at 72 h post dose. Conclusions: Systemic danofloxacin exposure achieved in horses following i.m. administration was consistent with the predicted blood levels needed for a positive therapeutic outcome for many equine infections. Conversely, danofloxacin utility by the i.g. route was limited by low bioavailability. Tolerability associated with i.m. administration was high. Conclusions: Pharmacokinetics, blood levels and good tolerability of i.v. and i.m. administration of danofloxacin in horses indicates that it is likely to be effective for treating sensitive bacterial infections.
Publication Date: 2006-07-27 PubMed ID: 16866202DOI: 10.2746/042516406777749245Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Randomized Controlled Trial

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research looks at the absorption and effect of the antibiotic danofloxacin in horses through different administration methods, namely intravenous (IV), intramuscular (IM) and intragastric (IG). The results suggest that injecting danofloxacin either intravenously or intramuscularly is more effective in treating bacterial infections in horses than administering it orally through the stomach.

Study Design and Methodology

  • The research was conducted using a cross-over design, which typically involves participants receiving multiple treatments in a randomized order over time. The same group of six healthy horses was administered danofloxacin in three separate phases, each time through a different route.
  • The pharmaceutical was administered at a dosage of 1.25 milligrams per kilogram of horse body weight, with a 15-day ‘washout’ period in between different methods of administration to eliminate any residual effects of the drug.
  • The researchers used High-Performance Liquid Chromatography (HPLC) with fluorescence detection to measure the concentration of danofloxacin in the horse’s plasma over time. This helped them understand how rapidly the drug is absorbed, distributed, metabolized, and eventually excreted by the body.
  • They also monitored creatine kinase (CK) activity at the site of intramuscular injections as an indication of any muscle damage or irritation caused by the drug administration.

Study Findings

  • The pharmacokinetic data obtained showed that danofloxacin present in horse’s blood after intravenous and intragastric administration followed a two-compartment open model, while intramuscular administration followed a one-compartment model. This shows differences in the way the drug was metabolized and distributed in the body based on its mode of administration.
  • The results showed that the drug was most effective when administered either via intravenous or intramuscular injection, due to its higher bioavailability – the proportion of the drug that entered circulation and was able to have an active effect. IV and IM administration had bioavailabilities of nearly 89% and over 22% respectively.
  • However, the researchers observed that the creatine kinase (CK) activity level, an indicator of muscle damage, increased three-fold above normal 12 hours after intramuscular administration, implying a slight discomfort or damage, though it did reduce approaching normal values by the 72nd hour post-administration.

Conclusion

  • Given the pharmacokinetics and blood levels achieved through intravenous and intramuscular administration routes, coupled with their higher bioavailability and tolerability, danofloxacin is likely to be effective for treating bacterial infections in horses when administered through these routes.
  • The study also points out that despite the convenience of oral administration, the intragastric route had limited efficacy, owing to its relatively low bioavailability.

Cite This Article

APA
Fernández-Varón E, Ayala I, Marín P, Carrión A, Martos N, Escudero E, Cárceles CM. (2006). Pharmacokinetics of danofloxacin in horses after intravenous, intramuscular and intragastric administration. Equine Vet J, 38(4), 342-346. https://doi.org/10.2746/042516406777749245

Publication

ISSN: 0425-1644
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 38
Issue: 4
Pages: 342-346

Researcher Affiliations

Fernández-Varón, E
  • Department of Pharmacology, Faculty of Veterinary Medicine, University of Murcia, Spain.
Ayala, I
    Marín, P
      Carrión, A
        Martos, N
          Escudero, E
            Cárceles, C M

              MeSH Terms

              • Animals
              • Anti-Bacterial Agents / administration & dosage
              • Anti-Bacterial Agents / adverse effects
              • Anti-Bacterial Agents / pharmacokinetics
              • Area Under Curve
              • Bacterial Infections / drug therapy
              • Bacterial Infections / veterinary
              • Biological Availability
              • Chromatography, High Pressure Liquid / methods
              • Chromatography, High Pressure Liquid / veterinary
              • Creatine Kinase / metabolism
              • Cross-Over Studies
              • Fluorescence
              • Fluoroquinolones / administration & dosage
              • Fluoroquinolones / adverse effects
              • Fluoroquinolones / pharmacokinetics
              • Horse Diseases / drug therapy
              • Horses
              • Injections, Intramuscular / veterinary
              • Injections, Intravenous / veterinary
              • Intubation, Gastrointestinal / veterinary

              Citations

              This article has been cited 1 times.
              1. Schrickx JA, Fink-Gremmels J. Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters.. Br J Pharmacol 2007 Feb;150(4):463-9.
                doi: 10.1038/sj.bjp.0706974pubmed: 17211460google scholar: lookup